Tumour recurrence is associated with Jass grouping but not with differences in E-cadherin expression in moderately differentiated Dukes' B colorectal cancers

Journal of Clinical Pathology

Volumn 50, Issue 3, 1997, Pages 218-222

  Ilyas, M ^a   Novelli, M ^b   Wilkinson, K ^a   Tomlinson, I P M ^b   Abbasi, A M ^a   Forbes, A ^a   Talbot, I C ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Colorectal cancer; E cadherin; Jass group; Tumour recurrence

Indexed keywords

CADHERIN;

ARTICLE; CANCER RECURRENCE; COLORECTAL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030955156     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.50.3.218     Document Type: Article

References (28)

1. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev 1993;15:499-545.
2. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987;i:1303-6.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
4. Costa A, Marasca R, Valentinis B, Savarino M, Faranda A, Silvestrini R, et al. p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 1995;176:45-53.
5. Nathanson SD, Linden MD, Tender P, Zarbo RJ, Jacobsen G, Nelson LT. Relationship among p53, stage, and prognosis of large bowel cancer. Dis Colon Rectum 1994;37:527-34.
6. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991;63:317-9.
7. Suzuki H, Matsumoto K, Koide A, Tada T, Fujino I, Okuda A, et al. Correlation of p53 with the clinicopathologic features and prognosis of colorectal adenocarcinoma. Surg Today 1994;24:85-7.
8. Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992;70:2778-84.
9. Zeng ZS, Sarkis AS, Zhang ZF, Klimstra DS, Charytonowicz E, Guillem JG, et al. p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994;12:2043-50.
10. Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development 1988;102: 639-55.
11. Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem 1990;59: 237-52.
12. Dogan A, Wang ZD, Spencer J. E cadherin expression in intestinal epithelium. J Clin Pathol 1995;48:143-6.
13. Cowin P. Unraveling the cytoplasmic interactions of the cadherin superfamily. Proc Natl Acad Sci USA 1994;91: 10759-61.
14. Gumbiner BM, McCrea PD. Catenins as mediators of the cytoplasmic functions of cadherins. J Cell Sci Suppl 1993;17:155-8.
15. Hinck L, Nathke IS, Papkoff J, Nelson WJ. Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol 1994; 125:1327-40.
16. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993;53:1696-701.
17. Pignatelli M, Ansari TW, Gunter P, Liu D, Hirano S, Takeichi M, et al. Loss of membranous E-cadherin expression in pancreatic cancer: correlation with lymph node metastasis, high grade, and advanced stage. J Pathol 1994; 174:243-8.
18. Schipper JH, Frixen UH, Behrens J, Unger A, Jahnke K, Birchmeier W. E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res 1991;51:6328-37.
19. Umbas R, Schalken JA, Aalders TW, Carter BS, Karthaus HF, Schaafsma HE, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-9.
20. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, et al. E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 1994;54: 3845-52.
21. Vleminckx K, Vakaet L, Mareel M, Fiers W, van-Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 1991;66:107-19.
22. Nigam AK, Savage FJ, Boulos PB, Stamp GW, Liu D, Pignatelli M. Loss of cell-cell and cell-matrix adhesion molecules in colorectal cancer. Br J Cancer 1993;68:507-14.
23. Kinsella AR, Lepts GC, Hill CL, Jones M. Reduced E-cadherin expression correlates with increased invasiveness in colorectal carcinoma cell lines. Clin Exp Metastasis 1994;12:335-42.
24. Dorudi S, Sheffield JP, Poulsom R, Northover JM, Hart IR. E-cadherin expression in colorectal cancer. An immunocytochemical and in situ hybridization study. Am J Pathol 1993;142:981-6.
25. Cowley GP, Smith ME. Modulation of E-cadherin expression and morphological phenotype in the intravascular component of adenocarcinomas. Int J Cancer 1995;60:325-9.
26. van-der-Wurff AA, Arends JW, van-der-Linden EP, ten-Kate J, Bosman FT. L-CAM expression in lymph node and liver metastases of colorectal carcinomas. J Pathol 1994; 172:177-81.
27. Dorudi S, Hanby AM, Poulsom R, Northover J, Hart IR. Level of expression of E-cadherin mRNA in colorectal cancer correlates with clinical outcome. Br J Cancer 1995;71: 614-6.
28. Gagliardi G, Kandemir O, Liu D, Guida M, Benvestito S, Ruers T, et al. Changes in E-cadherin immunoreactivity in the adenoma-carcinoma sequence of the large bowel. Virchows Arch 1995;426:149-54.